Search | Clinical Trials Finder

Conditions: Dry Eye
Interventions: Reproxalap Ophthalmic Solution (0.25% Novel Formulation) QID to BID, Vehicle Ophthalmic Solution (0.25% Novel Formulation) QID to BID; Drug
Lead sponsor: Aldeyra Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 206 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: Andover, Massachusetts

Conditions: Geographic Atrophy, Age-related Macular Degeneration
Interventions: LFG316, Sham, LFG316 Lower dose; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 55 Years and older
Enrollment: 158 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 19
States / cities: Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 15 more

Conditions: Keratoconus, Dry Eye, Allergy
Interventions: dexamethasone ophthalmic insert 0.4 mg, for intracanalicular use, Loteprednol Etabonate 0.38% Ophthalmic Gel/Jelly; Drug
Lead sponsor: Illinois College of Optometry; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Dry Eye Syndrome
Interventions: TheraTears lubricating drops; Other
Lead sponsor: Jenkins Eye Care; Other
Eligibility: 21 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Honolulu, Hawaii

Conditions: Dry Eye Disease
Interventions: rhNGF 5 μg/mL, rhNGF 10 μg/mL, Vehicle (Placebo solution); Drug
Lead sponsor: Dompé Farmaceutici S.p.A; Industry
Eligibility: 18 Years and older
Enrollment: 317 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 10
States / cities: Chandler, Arizona • Torrance, California • Colorado Springs, Colorado + 7 more

Conditions: Dry Eye Syndrome
Interventions: Formulation 1: Carboxymethylcellulose Sodium, Glycerin and Polysorbate 80, based artificial tear, Formulation 2: Carboxymethylcellulose Sodium, Glycerin and Polysorbate 80, based artificial tear, Glycerin and Polysorbate 80 based artificial tear; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: San Diego, California

Conditions: Age Related Macular Degeneration (ARMD)
Interventions: Elamipretide, Placebo; Drug
Lead sponsor: Stealth BioTherapeutics Inc.; Industry
Eligibility: 55 Years and older
Enrollment: 313 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 31
States / cities: Phoenix, Arizona • Sun City, Arizona • Huntington Beach, California + 28 more

Conditions: Sjogren's Syndrome, Dry Eye, Neurotrophic Keratitis
Interventions: Eye Exam; Diagnostic Test
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Dry Eye
Interventions: Miebo, Saline; Drug
Lead sponsor: Bausch & Lomb Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 216 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 12
States / cities: Glendale, California • Murrieta, California • Newport Beach, California + 9 more

Conditions: Dry Eye, Neuropathic Eye Pain, Ocular Microbiome, Depression, Anxiety
Interventions: Azithromycin Oral Product, Placebo Oral; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Sjogren's Syndrome
Interventions: Placebo, RO5459072; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 12
States / cities: Beverly Hills, California • Denver, Colorado • Baton Rouge, Louisiana + 9 more

Conditions: Dry Eye
Interventions: No topical artificial tear, Blink® Tears Lubricant Eye Drops; Drug
Lead sponsor: Innovative Medical; Industry
Eligibility: 21 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Scottsdale, Arizona

Conditions: Eye Disease
Interventions: Not listed
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: 2 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Keratoconjunctivitis Sicca
Interventions: Not listed
Lead sponsor: TearLab Corporation; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 314 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 6
States / cities: San Diego, California • Louisville, Kentucky • Chesterfield, Missouri + 3 more

Conditions: Dry Eye Disease
Interventions: SI-614, Placebo; Drug
Lead sponsor: Seikagaku Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 232 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 6
States / cities: Newport Beach, California • Louisville, Kentucky • Andover, Massachusetts + 3 more

Conditions: Dry Eye
Interventions: Lacrisert, 5 Mg Ophthalmic Insert; Drug
Lead sponsor: Virginia Eye Consultants; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Norfolk, Virginia

Conditions: Sjogren's Syndrome, Cough
Interventions: Dornase alfa, Saline; Drug
Lead sponsor: UConn Health; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Farmington, Connecticut

Conditions: Age-related Macular Degeneration
Interventions: VMS diary booklet, Standard of Care; Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: Not listed
Enrollment: 324 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Xerostomia, Sjogren's Syndrome
Interventions: NGX267; Drug
Lead sponsor: TorreyPines Therapeutics; Industry
Eligibility: 21 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 3
States / cities: Duncansville, Pennsylvania • Philadelphia, Pennsylvania • Austin, Texas

Conditions: Dry Eye Disease
Interventions: Not listed
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 946 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Dry Eye Syndromes
Interventions: Cyclosporine 0.05% Ophthalmic Emulsion; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 2
States / cities: Andover, Massachusetts • Memphis, Tennessee

Conditions: Dry Eye
Interventions: B & L Soothe Lubricant Eye Drops, Liposic EDO, OcuFresh Eye Wash; Drug
Lead sponsor: University of Rochester; Other
Eligibility: 30 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Dry Eye Disease (DED)
Interventions: acoltremon 0.003%; Drug
Lead sponsor: Center for Sight Las Vegas; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Dry Eye Syndromes
Interventions: Cyclosporine Ophthalmic Emulsion 0.05% (RESTASIS®), Artificial Tears REFRESH ENDURA®; Drug
Lead sponsor: Allergan; Industry
Eligibility: 21 Years to 50 Years
Enrollment: 137 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Overland Park, Kansas

Search by objective public record fields.

A Multi-Center, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Clinical Trial of Reproxalap to Assess the Safety and Efficacy in Subjects With Dry Eye Disease

Intravitreal LFG316 in Patients With Age-related Macular Degeneration (AMD)

Safety and Efficacy of Intracanalicular Dexamethasone Compared to Loteprednol Etabonate in Patients With Keratoconus

Changes in Tear Osmolarity Over Time With Sustained Use of TheraTears

A Safety and Efficacy Study of 2 Dosing Regimens of Recombinant Human Nerve Growth Factor (rhNGF) Eye Drop Solution Compared With Vehicle in Patients With Dry Eye Disease.

Safety and Tolerability of Artificial Tears in Dry Eye Subjects

ReNEW:Phase 3 Study of Efficacy, Safety & Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects With Dry Age-Related Macular Degeneration (Dry AMD)

Differences in Corneal Structure and Function in Patients With Sjogrens vs. Non-Sjogrens Dry Eye

A Study to Evaluate Corneal Endothelial Cell Density (ECD) in Subjects With Dry Eye Disease (DED) Administering Miebo® (Perfluorohexyloctane Ophthalmic Solution) for 12 Months.

Azithromycin for Meibomian Gland Disease

A Study to Assess the Efficacy of RO5459072 in Participants With Primary Sjogren's Syndrome

A Clinical Evaluation Pilot Study of the Efficacy of Blink® Tears Lubricant Eye Drops for the Relief of Dry Eye Symptoms Following Implantation of Tecnis® Multifocal Introcular Lens

Digital Photography to Evaluate Dry Eye

TearLab Core Validation Study to Establish Referent Values for Dry Eye Disease

A Study for Evaluation of the Efficacy and Safety of SI-614 Ophthalmic Solution in Patient With Dry Eye

An Open Label Comparing the Short Term Efficacy of Lacrisert

Pulmozyme for Sjogren's Associated Cough

Tools to Optimize Patient Presentation After Onset of Exudative Age-Related Macular Degeneration (AMD)

Study of NGX267 Oral Capsules in Patients With Xerostomia Associated With Sjorgren's Syndrome

Burden of Illness and Treatment Assessment of Patients With Dry Eye Disease: A Cross-Sectional Survey of Real-World Patients With Dry Eye Disease in the US

Evaluation of Maintaining Visual Performance in Participants Who Engage in Electronic Visual Tasking While Using Restasis®

Objective Evaluation of Ocular Surface Lubricants in Two Environments

Investigator Initiated Trial Using Dry Eye Surveys to Evaluate and Better Understand FDA Approved Acoltremon Treatment for Dry Eye Disease in Real World Treatment Settings (DESERT)

Safety and Efficacy Study of Cyclosporine Ophthalmic Emulsion in Post-LASIK Patients